Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (8)
Type
(
1 selected
)
Type
Guidance (284)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (16)
Medical technologies guidance (7)
Technology appraisal guidance (284)
Apply filters
Showing 51 to 75 of 284
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838
Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249
Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer TS ID 12010
Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy TS ID 11840
Technology appraisal guidance
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer TS ID 11933
Technology appraisal guidance
Delgocitinib for treating moderate to severe chronic hand eczema ID6408
Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps TSID 12012
Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392
Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981
Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Technology appraisal guidance
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial cancer with high microsatellite stability or mismatch repair proficiency ID6415
Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]
Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]
Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]
Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885
Technology appraisal guidance
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease [ID6235]
Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]
Technology appraisal guidance
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]
Technology appraisal guidance
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]
Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]
Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Technology appraisal guidance
Previous page
1
2
Current page
3
4
5
…
12
Page
3
of
12
Next page
Results per page
10
25
50
All
Back to top